Repligen (NASDAQ:RGEN) Earns "Buy" Rating from HC Wainwright

Key Points

• HC Wainwright reiterated a "buy" rating for Repligen, setting a target price of $180.00, suggesting a potential upside of 49.14% from the previous close.
• A total of eight analysts rate Repligen as a Buy, while three analysts have given it a Hold rating, leading to a consensus rating of "Moderate Buy."
• Repligen's stock performance shows a twelve-month low of $102.96 and a high of $182.52, with its last reported quarterly revenue being $182.37 million, exceeding analysts' expectations.

Repligen (NASDAQ:RGEN - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $180.00 target price on the biotechnology company's stock. HC Wainwright's price target would suggest a potential upside of 49.14% from the stock's previous close.

Several other equities analysts have also recently weighed in on RGEN. Barclays assumed coverage on shares of Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price for the company. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Evercore ISI reduced their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Wells Fargo & Company dropped their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $205.00 price target on shares of Repligen in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $169.55.

Repligen Stock Performance

NASDAQ RGEN opened at $120.69 on Wednesday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $102.96 and a twelve month high of $182.52. The business has a 50-day moving average price of $121.74 and a 200-day moving average price of $129.86. The firm has a market cap of $6.79 billion, a price-to-earnings ratio of -482.74, a price-to-earnings-growth ratio of 2.25 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's quarterly revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, Director Martin D. Madaus bought 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. lifted its holdings in shares of Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after acquiring an additional 594,189 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Repligen by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after buying an additional 430,039 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Repligen by 3,219.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company's stock worth $51,422,000 after buying an additional 400,970 shares during the period. Geneva Capital Management LLC raised its holdings in shares of Repligen by 239.6% in the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company's stock worth $60,639,000 after buying an additional 343,991 shares during the period. Finally, Blue Whale Capital LLP bought a new stake in shares of Repligen during the 2nd quarter worth approximately $35,782,000. Institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.